Revive Therapeutics

Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...

Two Binary Events Directly Ahead. As in Months Away, not Years. Share Price up 76% During April.
Revive Therapeutics

Revive Therapeutics (RVVTF, RVV): Updates and News Archive.

Recent Headlines (See FDA Filing Submission at Bottom) LIVE QUOTE

Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs

IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs

Ehave’s Mobile Ketamine Clinic, Rolling into Town.

Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch...
Psychedelic Stock Review

Coming This Monday..

Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November...

Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Not wanting to be caught...

Ehave (EHVVF) Announces Inclusion in the 2021 Psychedelic Investor Guide

MIAMI, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic...

MindMed (MNMD) IPO on Nasdaq: Becomes Second Public Psychedelic Company.

InvestmentU By Amber Deter Apr 27, 2021 at 12:55PM The MindMed IPO is making...
Ehave, Psychedelic Stock Review

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First...

Huge News at Ehave Inc.(EHVVF), our Favorite Psychedelic.

We just finished compiling the 2021 Psychedelic Investor Guide and reviewed 44 companies - in all shapes and sizes. Excluding Johnson &...

Latest article

Smart for Life (SMFL) Capitulates?

We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....

Althira (ATHA) $2.50, is Latest Alzheimer’s Trial Victim. Down 70%

Nearly 100 Alzheimer’s programs have failed in the past decade. Biotech investors should study or at least become...

Novogratz Remains Steadfast on Crypto, Says Wait Until Next Year (Bloomberg)

Great call. This was actually from Late 2018. (Bloomberg) — Billionaire investor Michael Novogratz is resolute when it...